Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dutasteride for Prostate Cancer Detection
NCT00398281Phase 3Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2006
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Dutasteride with Placebo (2 arms). Primary endpoints: Efficacy of short-term dutasteride in improving prostate cancer detection at Day 14, Detection rate of prostate cancer at Day 14 and 1 more. Started Nov 2006; status: completed.
02
Drugs
dutasteride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00398281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00398281.